<DOC>
	<DOCNO>NCT00529763</DOCNO>
	<brief_summary>The primary objective study estimate major cytogenetic response ( MCyR ) rate Dasatinib subject CP CML , complete overall hematologic response ( CHR OHR ) rate subject AD CML Ph+ ALL primary acquire resistance imatinib , intolerant imatinib , administer 100 mg QD ( Chronic CML ) 70mg BID ( AP CML Ph+ALL ) .</brief_summary>
	<brief_title>Dasatinib Imatinib Resistant/Intolerant Chinese CML ( Chronic Advanced Phase ) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Signed Written Informed Consent Men woman , age 18 year age old Subjects Chronic Phase ( CP ) Advanced Disease ( AD ) chronic myeloid leukemia ( CML ) /Ph+ Acute Lymphoblastic Leukemia ( Ph+ ALL ) Subjects resistant/intolerant imatinib Subjects present : 1 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) score 02 2 . Adequate hepatic function 3 . Adequate renal function 4 . Sodium , Potassium , Magnesium , Phosphorus , Calcium high equal low limit normal range Women child bear potential use adequate birth control Women pregnant breastfeeding Subjects eligible stem cell transplantation Serious uncontrolled medical disorder active infection Uncontrolled significant cardiovascular disease Concurrent incurable malignancy CML Subjects receive imatinib , interferon , cytarabine within 7 day antineoplastic agent hydroxyurea within 14 day dasatinib , Dasatinib past History significant bleeding unrelated CML</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic Phase , Advanced Phase chronic myeloid leukemia</keyword>
	<keyword>Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</keyword>
</DOC>